Terug
78
Ook genoteerd als
TKPHF
OTC
Dagbereik
€ 17,79
€ 17,99
52-Weeksbereik
€ 12,99
€ 18,82
Volume
3.227.688
50D / 200D Gem.
€ 17,61
/
€ 15,40
Vorige Slotkoers
€ 17,83
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,5 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 1,5 | 3,7 |
| Net Margin % | 2,4 | 3,8 |
| Rev Growth 5Y % | 9,4 | 10,0 |
| D/E | 0,7 | 0,2 |
Insider Trading Activity
8 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 28, 2026 |
Lo Andrew Tak Shing
Senior Managing Director
|
grant | 227.637 | — | — |
| Feb 28, 2026 |
Lo Andrew Tak Shing
Senior Managing Director
|
other | 66.848 | — | — |
| Feb 2, 2026 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 15.000 | — | — |
| Jan 26, 2026 |
Tak Paul Peter
Chief Executive Officer
|
grant | 629.000 | — | — |
| Aug 4, 2025 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 30.000 | — | — |
| Jun 25, 2025 |
Tak Paul Peter
Chief Executive Officer
|
grant | 42.826 | € 4,67 | € 199.997 |
| Jun 24, 2025 |
YU Wing Tak Wendy
Director
|
grant | 20.000 | — | — |
| May 5, 2025 |
Wu Ping Tak
VP, U.S. Operations
|
grant | 15.000 | — | — |
Belangrijkste Punten
Revenue grew 9,41% annually over 5 years — modest growth
Earnings declined -25,08% over the past year
ROE of 1,52% is below average
Generating 856,39B in free cash flow
P/E of 0,52 — trading at a low valuation
Cash machine — converts 793,48% of earnings into free cash flow
Groei
Revenue Growth (5Y)
9,41%
Revenue (1Y)7,45%
Earnings (1Y)-25,08%
FCF Growth (3Y)57,90%
Kwaliteit
Return on Equity
1,52%
ROIC2,24%
Net Margin2,36%
Op. Margin7,48%
Veiligheid
Debt / Equity
0,65
Current Ratio1,01
Interest Coverage2,50
Waardering
P/E Ratio
0,52
P/B Ratio0,01
EV/EBITDA12,22
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,45% | Revenue Growth (3Y) | 6,66% |
| Earnings Growth (1Y) | -25,08% | Earnings Growth (3Y) | -41,65% |
| Revenue Growth (5Y) | 9,41% | Earnings Growth (5Y) | -26,80% |
| Profitability | |||
| Revenue (TTM) | 4,58T | Net Income (TTM) | 107,93B |
| ROE | 1,52% | ROA | 0,76% |
| Gross Margin | 65,51% | Operating Margin | 7,48% |
| Net Margin | 2,36% | Free Cash Flow (TTM) | 856,39B |
| ROIC | 2,24% | FCF Growth (3Y) | 57,90% |
| Safety | |||
| Debt / Equity | 0,65 | Current Ratio | 1,01 |
| Interest Coverage | 2,50 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 0,52 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | -2,57 |
| EV/EBITDA | 12,22 | Dividend Yield | 0,04% |
| Market Cap | 56,42B | Enterprise Value | 4,19T |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 4,58T | 4,26T | 4,03T | 3,57T | 3,20T |
| Net Income | 107,93B | 144,07B | 317,02B | 230,06B | 376,01B |
| EPS (Diluted) | 33,62 | 45,58 | 100,97 | 72,94 | 119,48 |
| Gross Profit | 3,00T | 2,83T | 2,78T | 2,46T | 2,20T |
| Operating Income | 342,59B | 214,08B | 490,51B | 460,84B | 509,27B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 14,25T | 15,11T | 13,96T | 13,18T | 12,91T |
| Total Liabilities | 7,31T | 7,83T | 7,60T | 7,49T | 7,74T |
| Shareholders' Equity | 6,94T | 7,27T | 6,35T | 5,68T | 5,17T |
| Total Debt | 4,52T | 4,84T | 4,38T | 4,35T | 4,64T |
| Cash & Equivalents | 385,11B | 457,80B | 533,53B | 849,70B | 966,22B |
| Current Assets | 2,52T | 2,56T | 2,40T | 2,59T | 2,71T |
| Current Liabilities | 2,51T | 2,31T | 2,48T | 2,15T | 1,77T |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#44 of 1024
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026